Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TNBC

- PMLiVE

FDA starts speedy review of Merck’s Ebola vaccine

First company to file for approval in the US

- PMLiVE

Boehringer bags FDA OK for Ofev in rare lung disease ILD

First drug approved for condition

- PMLiVE

Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation

Provides hope for new treatment of rare cancer

Roche Basel Switzerland

Roche scores EU approval twice for Tecentriq in lung cancer

Carves out space in a market dominated by MSD's Keytruda

- PMLiVE

MSD’s Keytruda catches up in kidney cancer

Combination therapy approved in EU for all risk groups

- PMLiVE

Tecentriq approved in Europe for triple negative breast cancer

Roche can dominate in niche setting

- PMLiVE

Finch Therapeutics bags $53m for microbiome therapies

In race to be first-to-market in C diff

- PMLiVE

BeiGene gets speedy US review for lymphoma drug zanubrutinib

First US filing is major milestone for Chinese firm

Novartis day

Senators attack Novartis over ‘unconscionable’ handling of Zolgensma data

Ask FDA to hold the company ‘accountable’

- PMLiVE

ICER closely monitoring FDA’s Zolgensma investigation

Could affect initial cost assessment

- PMLiVE

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

Proves continuing dominance in this indication

- PMLiVE

DBV refiles peanut allergy immunotherapy in the US

Follows initial manufacturing concerns

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links